GOLDEN, Colo.--(BUSINESS WIRE)--A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV). Previous studies have shown that two doses of intradermally-delivered IPV (60% less vaccine) were more immunogenic than one full dose delivered intramuscularly. Intradermal fractional dose delivery also lowers the total cost of vaccination substantially.
Intradermal delivery with needle and syringe is difficult for mass vaccination campaigns as it requires significant training to master, resulting in inconsistent results. The article identifies an alternative, the PharmaJet Tropis® Needle-free injection system (NFIS). As part of the World Health Organization’s campaign to eradicate polio, over 500,000 children were vaccinated with the Tropis NFIS in a one-week period in 2019. Another 1 million children were vaccinated in early 2020. Vaccinators and caregivers, who previously used needle and syringe, expressed a strong preference for the PharmaJet Tropis. In particular, they cited ease and speed of use and the childrens’ response to the vaccination (less discomfort/crying), which led to a nearly 20% increase in vaccine campaign participation.1 The PharmaJet Needle-free system has significantly faster preparation and administration time compared to the traditional ID technique with needle and syringe. It requires minimal training, and virtually eliminates vaccine wastage, making it an excellent tool for mass vaccination campaigns and routine use.
“The PharmaJet Needle-free injection system has been shown to improve the immune response of multiple vaccines and has a robust safety profile,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “It is ideal for delivery of intradermal polio vaccinations given its consistency and the improved immune response of 2 fractional ID doses versus 1 full intramuscular dose. Initially we got involved with polio vaccine delivery to solve a supply issue, but we now know needle-free delivery of IPV and other vaccines has many other benefits with improved effectiveness, a high level of safety, lower total costs and wastage, and increased coverage.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Data on file
About PharmaJet
PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. An FDA Master File was established in August of 2017 as a precursor to 510(k) and Tropis received WHO Pre-Qualification (PQS) in June 2018. The PharmaJet Needle-free Injectors are safe, fast, and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com. Follow us on LinkedIn.
